Marker sequences for diagnosing and stratifying systemic sclerosis patients

ABSTRACT

The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 16703336 Sequence Listing.txt, created Jun. 10, 2020, which is 41,588 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

This application is a continuation application of U.S. application Ser. No. 15/324,470, filed Jan. 6, 2017, which is a national stage of International Application No. PCT/EP2015/065268, filed Jul. 4, 2015, which claims priority to European Application No. 14176035.5, filed Jul. 7, 2014. The disclosures of the above applications are incorporated herein by reference in their entireties.

The present invention relates to methods for identifying markers for systemic sclerosis (SSc; also scleroderma or Progressive Systemic Sclerosis (PSS)) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc subgroups.

SSc is a chronic, inflammatory, rheumatic disease, which counts among the classic immunological connective tissue diseases (collagenoses). SSc is a heterogeneous disease with excessive fibrosis of the skin. Further organ systems, such as the lungs, gastrointestinal area, kidneys, heart and blood vessels can also be affected. In addition, joint symptoms (arthritis) also occur.

SSc is a very rare disease. The incidence is approximately 0.5-1.5/100,000 individuals/year. It mostly occurs between the ages of 30 and 50. Women are 10-15 times more likely to be affected than men (LeRoy et al. 1988).

Clinically, a distinction can be made between limited and diffuse SSc in accordance with LeRoy et al. (1998). In early phases of the disease, it is often difficult to classify patients unambiguously, with this being referred to as undifferentiated SSc. If, in addition to scleroderma, fundamental symptoms of other rheumatic diseases also occur, reference is made to scleroderma overlap syndrome or overlap syndrome.

The limited form of SSc occurs at a frequency of up to 60%. This is characterised by fibrosis of the hands and feet, which spreads to below the elbows and knee joints. Raynaud's phenomenon often exists already for many years prior to the appearance of skin fibrosis. Gastrointestinal changes (difficulty in swallowing) and pulmonary arterial hypertension (PAH) also often, occur. The limited form also includes CREST syndrome: calcinosis cutis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.

The diffuse form is the quicker and more severe form of SSc. In this case the fibrosis spreads past the elbows over the body and face. In contrast to the limited form, skin fibroses occur already 1-2 years after the appearance of Raynaud's phenomenon.

In the case of scleroderma overlap syndrome, symptoms of further non-organ-specific autoimmune diseases, such as myositis, lupus erythematosus/SLE, Sjogren's syndrome, and rheumatoid arthritis/RA, also occur in addition to the skin symptoms of scleroderma.

Patients with undifferentiated SSc have Raynaud's syndrome and have the swollen fingers typical of SSc and pulmonary arterial hypertension. Only some of the patients later actually develop diffuse or limited SSc.

The diagnosis of SSc can be provided on the basis of the clinical picture with the typical skin changes. This can be difficult, however, in the early stages of the disease. In addition, the detection of antinuclear antibodies (ANAs) is used. ANAs can be detected in approximately 90% of SSc patients. However, the ANA test is not specific for SSc, since other collagenoses and up to 20% of healthy individuals will test positively. The three most important autoantibodies in the case of SSc are anti-topoisomerase I (Scl-70), anti-centromere (CENP), and anti-RNA polymerase III (anti-RNAP III). These autoantibodies have a high specificity for SSc and are often associated with a subform of SSc. However, these autoantibodies are suitable only to a limited extent for subtyping of SSc, since they do not occur exclusively in one subtype and their frequency can deviate distinctly in different ethnicities. Anti-topoisomerase antibodies nave a high specificity for SSc and are detectable in approximately 30% of patients having diffuse SSc. Anti-centromere antibodies are, by contrast, detectable in approximately 50-60% of patients having limited SSc and in 10% of patients having diffuse SSc. The two autoantibodies are mutually exclusive and are detectable jointly in patients only in very rare cases. Anti-RNAP III antibodies are detectable more frequently in the diffuse form and constitute a risk factor for renal crisis. On the whole, only approximately 70% of SSc patients can be identified diagnostically using the autoantibodies against anti-topoisomerase, anti-centromere and anti-RNAP (Mierau et al. 2011; Mehra et al. 2013).

Antibodies against U1-RNP and PM-Scl antibodies also occur more rarely. These, however, have only a low specificity for SSc: anti-PM-Scl antibodies are often detected in patients having polymyositis/SSc overlap syndrome. Antibodies against U1-RNP are detectable both in the case of SSc and in the case of mixed connective tissue diseases (MCTD) and SLE. In approximately one third of patients, antibodies against typical collagenosis antigens, such as Rho52/SS-A, Ro60/SS-B, and citrullinated peptides (ACPA) and rheumatoid factors are also detected.

In clinical practice, the diagnosis of an early form of SSc and classification thereof into the subgroups constituted by diffuse, limited or overlap syndrome is often difficult, since not all symptoms are yet present or approximately 10-30% of patients carry symptoms of a different collagenosis (connective tissue disease). Since the various subforms have a very different prognosis, there is a substantial need for biomarkers for improved diagnosis of SSc and for a classification into SSc subgroups. There is also a great need for prognostic and predictive biomarkers.

A further problem of the currently used diagnostic methods is that the suitability of the previously tested autoantigens for the diagnosis of organ involvement and complications is disputed, and partly conflicting data has been published. Furthermore it is desirable with respect to the application in individualized medicine to have markers available that are easy to produce and handle, opening up a broad field of diagnostic applications.

This object is achieved in accordance with the invention by markers that detect certain characteristic regions of autoantigens related to SSc. These characteristic regions are one or more short sequences, which optionally may be modified and, either alone or collectively, form a pattern characteristic of SSc and/or one or more SSc subgroups. These short makers are easy to produce and handle and open up a broad field of practical diagnostic applications within the scope of individualized medicine.

The term systemic sclerosis (SSc) is defined for example in Pschyrembel, Clinical Dictionary (2012 edition, DE GRUYTER).

The invention thus relates to a marker for detecting systemic sclerosis (SSc), characterised in that the marker comprises one or more peptide sequences having a respective length of no more than 35 amino acids.

In a preferred embodiment, the marker according to the invention is characterised in that the one or more peptide sequences have a respective length of no more than 25 amino acids.

In a further preferred embodiment, the marker according to the invention is characterised in that the one or more peptide sequences have a respective length of no more than 15 amino acids, and preferably of no more than 12 or 13 amino acids.

In a further embodiment of the invention, the marker is a binding region.

In a further embodiment of the invention, the marker is an epitope. The epitope can, for example, be a linear or a conformational epitope.

In a further preferred embodiment, the marker according to the invention is characterised in that the peptide sequence is selected from, or the peptide sequences are selected independently of one another from.

SEQ ID No. 1 SPQPSASSSSQFSTSGGPWARERRAGEEPV SEQ ID No. 2 LPAPLPPSHGSS SEQ ID No. 3 SPQPSASSSSQF SEQ ID No. 4 SSQFSTSGGPWAR SEQ ID No. 5 REKLNPPTPSIYL SEQ ID No. 6 GGPWARERRAGEEPV SEQ ID No. 7 PREKLNPPTPSIYL SEQ ID No. 8 YQYQLALERYEWNEV SEQ ID No. 9 PRRRSRKPEAPRRRSPSPTPTPGPSRRGPSLGAS SEQ ID No. 10 SPSPTPTPGPSR SEQ ID No. 11 GPSRRGPSLGAS SEQ ID No. 12 TPTPGPSRRGPS SEQ ID No. 13 RSPSPTPTPGPSR SEQ ID No. 14 PRRRSRKPEAPR SEQ ID No. 15 RSPSPTPTPGPSR SEQ ID No. 16 APRRRSPSPTPTPGP SEQ ID No. 17 RRRSPSPTPTPGPSR SEQ ID No. 18 SPSPTPTPGPSRRGP, homologues of sequences SEQ ID No. 1 to 18 with at least 95% homology, subsequences of SEQ ID No. 1 to 18 and subsequences of homologues of SEQ ID No. 1 to 18 with at least 95% homology.

In a preferred embodiment, the marker comprises SEQ ID No. 2.

In a preferred embodiment, the marker comprises SEQ ID No. 3.

In a preferred embodiment, the marker comprises SEQ ID No. 4.

In a preferred embodiment, the marker comprises SEQ ID No. 5.

In a preferred embodiment, the marker comprises SEQ ID No. 2 and SEQ ID No. 3.

In a preferred embodiment, the marker comprises a subsequence of SEQ ID No. 1. The subsequence preferably has a length of 12 or 13 amino acids.

In a preferred embodiment, the marker comprises at least two subsequences of SEQ ID No. 1. The subsequences preferably have a length of 12 or 13 amino acids.

In a preferred embodiment, the marker comprises SEQ ID No. 10.

In a preferred embodiment, the marker comprises SEQ ID No. 11.

In a preferred embodiment, the marker comprises SEQ ID No. 12.

In a preferred embodiment, the marker comprises SEQ ID No. 13.

In a preferred embodiment, the marker comprises SEQ ID No. 14.

In a preferred embodiment, the marker comprises SEQ ID No. 10 and SEQ ID No. 11.

In a preferred embodiment, the marker comprises a subsequence of SEQ ID No. 9. The subsequence preferably has a length of 12 or 13 amino acids.

In a further embodiment of the invention, the marker is characterised in that the marker comprises one or more sequences that code for one or more of the peptide sequences SEQ ID No. 1-18, one or more homologues of sequences SEQ ID No. 1 to 18 with at least 95% homology, one or more subsequences of SEQ ID No. 1 to 18, one or more subsequences of the homologues of SEQ ID No. 1 to 18 with at least 95% homology.

The invention also relates to the use of at least, one marker according to the invention. The invention relates to the use of at least one marker according to the invention for diagnosis, for example for early diagnosis or for differential diagnosis, in particular for distinguishing SSc from other autoimmune diseases or from rheumatic diseases. The invention relates to the use of at least one marker according to the invention for prognosis. The invention relates to the use of at least one marker according to the invention for therapy control, for example for active substance selection and/or for selecting the dosage. The invention relates to the use of at least one marker according to the invention for therapy monitoring. The invention relates to the use of at least one marker according to the invention for stratification. The invention relates to the use of at least one marker according to the invention for aftercare in the case of SSc.

The invention relates to the use of at least one marker according to the invention for identifying SSc subgroups. The invention relates to the use of at least one marker according to the invention for the diagnosis of SSc subgroups, for example for the early diagnosis or for the differential diagnosis of SSc subgroups, in particular for distinguishing individual SSc subgroups from other SSc subgroups and/or from other autoimmune diseases or rheumatic diseases. The invention relates to the use of at least one marker according to the invention for the prognosis of individual SSc subgroups. The invention relates to the use of at least one marker according to the invention for therapy control in individual SSc subgroups, for example for active substance selection and/or for selecting the suitable dosage for individual SSc subgroups. The invention relates to the use of at least one marker according to the invention for the therapy monitoring of individual SSc subgroups. The invention relates to the use of at least one marker according to the invention for the stratification of individual SSc subgroups. The invention relates to the use of at least one marker according to the invention for the aftercare of individual SSc subgroups. SSc subgroups are, for example, diffuse SSc (dSSc), limited SSc (1SSc) or SSc overlap syndrome (SSc-OS). For example, the marker SEQ TD No. 3 is suitable for this use. For example, the marker SEQ ID No. 4 is suitable for this use. For example, the marker SEQ ID No. 5 is suitable for this use. For example, the marker SEQ ID No. 12 is suitable for this use. For example, the marker SEQ ID No. 13 is suitable for this use. For example, the marker SEQ ID No. 14 is suitable for this use. Combinations of the aforementioned sequences are also suited.

The invention also relates to a panel (arrangement) of markers for use with SSc, comprising at least one marker according to the invention. The invention also relates to a panel of markers for use with SSc, comprising at least two markers according to the invention. The invention also relates to a panel of markers for use with SSc, comprising at least three or four markers according to the invention. Corresponding panels can include further markers or components. The invention relates to a panel of markers for SSc or SSc subgroups, comprising at least two different markers selected independently of one another from the sequences SEQ ID No. 1 to 18, homologues of sequences SEQ ID No. 1 to 18 with at least 95% homology, and subsequences of SEQ ID No. 1 to 18 and subsequences of homologues of SEQ ID No. 1 to 18 with at least 95% homology.

The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 2 and SEQ ID No. 3. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 10 and SEQ ID No. 11. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 10. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 11. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 2, SEQ ID No. 10 and SEQ ID No. 11. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 3, SEQ ID No. 10 and SEQ ID No. 11. The invention relates to a panel of markers for use with SSc comprising SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 10 and SEQ ID No. 11. A person skilled in the art will be able to compile further panels by appropriately combining the markers according to the invention in analogous fashion.

On account of the high clinical and serological heterogeneity of the SSc disease, it is difficult to diagnose SSc unambiguously using just one biomarker. It is therefore often necessary to combine (where possible) uncorrelated autoantigens to form what are known as panels of markers (biomarker panels for SSc). For example, within the scope of individualised medicine, corresponding panels of markers for SSc can be composed individually for the relevant SSc subtype (subgroup) for individual patients or patient groups. A corresponding panel can be embodied for example in the form of an arrangement, an array, or also one or more beads. The invention thus relates to an arrangement comprising one or more markers according to the invention, a protein array comprising one or more markers according to the invention, and a bead (pellet or platelet) comprising one or more markers according to the invention.

The invention also relates to a diagnostic device for use with SSc, comprising at least one marker according to the invention or at least one panel according to the invention. The invention also relates to a test kit for use with SSc, comprising at least one marker according to the invention or at least one panel according to the invention.

The invention also relates to a method for the diagnosis, for example for the early diagnosis and/or for the differential diagnosis of SSC. The invention also relates to a method for the prognosis of SSc. The invention also relates to a method for therapy control, for example for active substance selection and/or for selecting the dosage in the case of SSc. The invention also relates to a method for the therapy monitoring of SSc. The invention also relates to a method for the aftercare of SSc. Corresponding methods can comprise the following steps:

-   -   a. Bringing at least one marker according to the invention, for         example a binding region or an epitope or a panel according to         the invention or an antibody according to the invention     -   b. into contact with bodily fluid or a tissue sample from an         individual to be tested, and     -   c. detecting an interaction of the bodily fluid or of the tissue         sample with the one or more markers or the panel or the antibody         from a.

The invention also relates to a composition comprising at least one marker according to the invention, for example a binding region or an epitope. The invention also relates to a pharmaceutical composition for specific application in the case of SSc, which comprises at least one marker according to the invention. The invention also relates to a drug for specific application in the case of SSc, which comprises at least one marker according to the invention. Corresponding (pharmaceutical) compositions and drugs can comprise further additives and/or auxiliary agents.

The invention also relates to an antibody for specific application for the treatment of SSc. The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one binding region according to the invention or an epitope according to the invention. The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one epitope according to the invention. The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one peptide sequence SEQ ID No. 1 to The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one homologue of the peptide sequence SEQ ID No. 1 to 18 with at least 95% homology. The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one subsequence SEQ ID No. to 18. The invention relates to an antibody for specific application for the treatment of SSc, comprising at least one subsequence of the homologues of SEQ ID No. 1 to 18 with at least 95% homology.

The invention also relates to a target for the therapy of SSc selected from the markers according to the invention, for example a binding region or an epitope, for example selected from sequences SEQ ID No. 1 to 18, the homologues of sequences SEQ ID No. 1 to 18 with at least 95% homology, the subsequences of SEQ ID Mo. 1 to 18 and the subsequences of the homologues of SEQ ID No. 1 to 18 with at least 95% homology, and the nucleic acids coding for sequences SEQ ID No. 1 to 18, the homologues thereof, subsequences and homologues of the subsequences.

In a further embodiment, the invention relates to a drug or an active substance or a prodrug developed for SSc and obtainable through the use of an SSc marker according to the invention.

One embodiment of the composition is an affinity material comprising one or more markers according to the invention. The affinity material can be used, for example, for carrying out an apharesis or blood washing for patients with SSc. The invention thus relates to the use of the markers according to the invention, preferably in the form of an arrangement, as affinity material for carrying out a blood washing in the broader sense, wherein substances from bodily fluids from a patient with SSc, such as blood or plasma, bind to the markers according to the invention and consequently can be removed selectively from the bodily fluid.

The invention also relates to a method for screening active substances for use with SSc, in which

-   -   a. at least one marker according to the invention, for example a         binding region or an epitope or a panel according to the         invention or an antibody according to the invention     -   b. is brought into contact with a substance to be analyzed, and     -   c. an interaction of the substance to be analyzed with the one         or more markers, the panel or the antibodies from a. is         detected.

The invention relates to the use of one or more markers according to the invention together with already known and/or new active substances (companion diagnostics). The invention relates to the use of one or more markers according to the invention for defining patient groups, for example to recruit dSSc, 1SSc or SSc-OS subgroups for drug studies. The invention relates to the use of one or more markers according to the invention for identifying specific antibody signatures in SSc patient subgroups. The invention relates to the use of one or more markers according to the invention for the individually tailored diagnosis and/or therapy of individual patients, patient groups, cohorts, population groups, variants of SSc, and stages of SSc. The invention relates to the use of one or more markers according to the invention for the analysis of autoantibody profiles of patients, in particular for the qualitative and/or quantitative analysis of autoantibodies and/or for monitoring changes of autoantibody profiles associated with SSc or SSc subgroups, for example in bodily fluids such as serum, tissue or tissue samples of the patient. The invention essentially relates to the use of one or more markers according to the invention, in which the detection of an interaction of the bodily fluid or of the tissue sample and the one or more markers according to the invention is carried out, thereby mapping an SSc- or SSc-subgroup-associated autoantibody profile of the patient or of a cohort or of a population group. The invention relates to the use of one or more markers according to the invention, in which the detection of an interaction of the bodily fluid or of the tissue sample with the one or more markers according to the invention allows the prediction of a course of the disease (prognosis). The invention relates to the use of one or more markers according to the invention, in which the detection of an interaction of the bodily fluid or of the tissue sample with the one or more markers according to the invention, enables a prediction with respect to a response or non-response to a therapy or an active substance (such as therapy control, active substance selection). The invention relates to the use of one or more markers according to the invention for the analysis of autoantibody profiles of patients, in particular for the quantitative analysis and/or for the monitoring of changes of autoantibody profiles of SSc patients. An interaction of the bodily fluid or of the tissue sample with the one or more SSc markers can be detected, for example, by a probe, in particular by an antibody.

In a preferred embodiment at least 2, for example 3, 4, 5, 6, 7, 8, 9, 10 or more markers according to the invention are used together or in combination, either simultaneously or in succession.

The invention comprises the markers according to the invention on a solid substrate, for example a filter, a membrane, a small platelet or ball, for example a magnetic or fluorophore-labelled ball, a silicon wafer, a bead, a chip, a mass spectrometry target, or a matrix, or the like. Different materials are suitable as substrates and are known to a person skilled in the art, for example glass, metal, plastic, filter, PVDF, nitrocellulose, or nylon (for example Immobilon P Millipore, Protran Whatman, Hybond N+ Amersham).

The substrate for example can correspond to a grid with the dimensions of a microtitre plate (8-12 well strips, 96 wells, 384 wells or more), of a silicon wafer, of a chip, of a mass spectrometry target, or of a matrix. In one embodiment of the panel, the particular SSc marker can be represented in different quantities in one or more regions of the panel. This allows a variation of the sensitivity. The regions may each have a totality of SSc markers, that is to say a sufficient number of different SSc markers, in particular 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more, to 50 (numerically) or more, preferably more than 100, particularly preferably 150 or more, for example 25,000 or 5,000 or 10,000. It is possible to use identical markers and/or different markers.

A “protein array” in the sense of this invention is the systematic arrangement of SSc markers on a solid substrate, wherein the substrate can have any shape and/or size, and wherein the substrate is preferably a solid substrate.

The SSc markers of the arrangement are fixed on the substrate preferably spotted or immobilised, printed on or the like, in particular in a reproducible manner. One or more SSc markers can be present multiple times in the totality of all SSc markers and may be present in different quantities based on a spot. Furthermore, the SSc markers can be standardised on the substrate (for example by means of serial dilution series of, for example, human globulins as internal calibrators for data normalisation and quantitative evaluation). A standard (for example a gold standard) can also be applied to the substrate where necessary. In a further embodiment, the one or more SSc markers are present in the form of clone sequences or clones.

In the uses or applications described in the present, application, the markers according to the invention can be combined, supplemented or extended with known biomarkers for SSc or biomarkers for other diseases. With a combination of this type, a proportion of markers according to the invention of preferably at least 50%, preferably 60%, and particularly preferably 70% or more is comprised.

In a preferred embodiment, the use of the SSc markers is implemented outside the human or animal body, for example the diagnosis is performed ex vivo/in vitro.

In the sense of this invention, the term “diagnosis” means the positive determination of SSc with the aid of the markers according to the invention and the assignment of the patients or symptoms thereof to the disease SSc. The term ‘diagnosis’ comprises medical diagnostics and examinations in this regard in particular in vitro diagnostics and laboratory diagnostics as well as proteomics and nucleic acid blotting. Additional examinations may be required for validation and to exclude other illnesses. The term ‘diagnosis’ therefore includes in particular the differential diagnosis of SSc by means of the markers according to the invention.

In the sense of this invention, “stratifying (also: stratification) or therapy control” means that, for example, the methods according to the invention allow decisions for the treatment and therapy of the patient, whether it is the hospitalisation of the patient, the use, efficacy and/or dosage of one or more drugs, a therapeutic measure or the monitoring of the course of a disease and the course of therapy or aetiology or classification of a disease, for example into a new or existing sub-type, or the differentiation of diseases and patients thereof. In a further embodiment of the invention, the term “stratification” in particular includes the risk stratification with the prognosis of an “outcome” of a negative health event. The stratification of patients with SSc into new or established SSc subgroups as well as the expedient selection of patient groups for the clinical development of new therapeutic agents is also included. The term ‘therapy control’ also includes dividing the patients into responders and non-responders with respect to a therapy or the treatment course thereof.

In accordance with the invention, “therapy control” means, for example, the prediction and monitoring of the response to a drug or to a therapy as well as aftercare.

“Prognosis” means the prediction of the course of a disease.

Within the scope of this invention, the term “patient” is understood, to mean any test subject, any individual (human or mammal), with the provision, that the test subject or individual is tested for SSc.

Markers according to the invention are nucleic acid sequences and/or amino acid sequences, preferably amino acid sequences according to the definition, in the appended sequence listing (SEQ ID No. 1 to SEQ ID No. 18), homologues and subsequences thereof, wherein modified nucleic acid and amino acid sequences are also included. The marker according to the invention can result in an interaction with SSc-specific substances from the bodily fluid or tissue sample from a patient with SSc (for example antigen (epitope)/antibody (paratope) interaction). The SSc-specific substances from the bodily fluid or tissue sample occur either only in an amplified manner or at least in an amplified manner in the case of SSc or are expressed, whereas these substances are not present in patients without SSc or healthy individuals, or at least are present, to a lesser extent (smaller amount, lower concentration). The markers according to the invention for SSc are additionally characterised in that they interact with substances from the bodily fluid or tissue sample from patients with SSc, because certain substances no longer occur or are no longer expressed or occur or are expressed at least in a much lower amount/concentration in the case of SSc, whereas these substances are present or are at least present to a much higher extent in patients without SSc. Markers for SSc can also be present in healthy test subjects, however the amount (concentration) thereof changes, for example, with the development, establishment and therapy of SSc. One or more markers can in this way map a profile of substances from bodily fluid and tissue sample, for example an SSc-associated autoantibody profile of the patient in question. Markers according to the invention are biomarkers for SSc.

In a particularly preferred embodiment, the marker according to the invention identifies and/or binds to autoantibodies which are present (intensified) or are present to a lower extent (or no longer) during the course of the development, establishment and therapy of SSc. Within the scope of the present invention, the autoantibodies which are formed with the occurrence and during the course of the development of SSc and/or of which the expression is up-regulated or down-regulated are detected in particular. These autoantibodies can be detected with the aid of the methods and markers according to the invention, and the detection and monitoring (for example of the amount) thereof can be used for the early identification, diagnosis and/or therapy monitoring/therapy control and the prognosis and prediction of the risk of the re-occurrence of SSc within the scope of the aftercare.

The autoantibody profiles can be sufficiently characterised with the use of just a single SSc marker. In other cases, two or more SSc markers are necessary in order to map an autoantibody profile which is specific for SSc. The number of markers used can differ, for example, within the scope of the use in diagnostic devices. While rapid or routine tests, which the patient carries out at home, comprise only one, 2, 3 or 4 (few) markers, a highly sensitive diagnostic test can comprise several to many, such as 5-20 or more, markers.

In one embodiment of the invention, autoantibodies can be detected using SSc markers; for example, these are homologues of the sequences SEQ ID No. 18. In another embodiment of the invention, these autoantibodies can be detected using SSc markers which derive from the same individual. Autoantibodies can be formed by the patient, already many years prior to the occurrence of the first symptoms of disease. An early identification, diagnosis and also prognosis and preventative treatment or lifestyle change and other possibilities for prevention would, therefore be possible years prior to the visible outbreak of the disease. The devices, means and methods according to the invention thus enable a very early intervention compared with known methods, which significantly improves the prevention, treatment possibilities and effects of SSc.

Since the SSc-associated autoantibody profiles change during the establishment and treatment/therapy of SSc, the invention also enables the detection and monitoring of SSc at any stage of the development and treatment and also monitoring within the scope of SSc aftercare. The means according to the invention, for example a corresponding diagnostic device or a test kit, also allow simple handling at home by the patient and an economical routine precautionary measure for early identification.

Compared with other biomarkers, the detection of SSc-associated autoantibodies for example in the serum or plasma of patients has the advantage of high stability and storage capability and good detectability. The presence of autoantibodies also is not subject to a circadian rhythm, and therefore the sampling is independent of the time of day, food intake, and the like.

The invention relates to the use of one or more markers according to the invention for the detection in a bodily fluid, in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid or a tissue sample from the patient. The invention relates in particular to the use of the markers according to the invention on these bodily fluids and tissue samples for early detection, diagnosis, prognosis, therapy control and aftercare. However, this list is not exhaustive and it is also possible, for example, to couple these with DNA tests.

Homologues of the markers SEQ ID No. 1 to 18 according to the invention are included. Within the sense of the invention, homologues are those with homology of the amino or nucleic acid sequence (sequence homologues) and those in which the corresponding sequence is modified, for example the protein variants, which have the same amino acid sequence, but differ with regard to the modification, in particular the post-translational modification. In accordance with the invention, modifications of the nucleic acid sequence and of the amino acid sequence, for example citrullination, acetylation, phosphorylation, glycosylation, methylation, or polyA strand extensions and further modifications known as appropriate to a person skilled in the art are included.

Sequence homologues of the markers and the subsequences thereof are nucleic acid sequences and/or protein sequences. Sequence homologues of the markers SEQ ID No. 1-18 are protein sequences that have an identity of at least 90%, preferably 95%, particularly preferably 96% or 97% or more, for example 98% or 99%. Sequences that, in addition to sequences SEQ ID No. 1 to 18, also comprise further sequences are also included in accordance with the invention, wherein these further sequences, however, are not identical to those of the native protein in question from which the markers according to the invention derive. In accordance with the invention, proteins and peptides that comprise one or more of the markers according to the invention, but are not identical to the native proteins in question from which the markers according to the invention are derived, are also included. In accordance with the invention, nucleic acids that code for the protein sequence of the homologues are also included.

The invention also relates to subsequences of the markers according to the invention with the sequence SEQ ID No. 1 to 18 and the homologues thereof. Subsequences are those amino acid sequences that are shortened compared with the entire sequence SEQ ID No. 1 to 18. Here, the deletion may occur at the end or the ends and/or within the peptide sequence. For example, subsequences that have one amino acid less than the sequences SEQ ID No. 1 to 18 are comprised. Subsequences that have 2 fewer amino acids than the sequences SEQ ID No. 1 to 18 are also comprised. For example, subsequences that have 3 fewer amino acids than the sequences SEQ ID No. 1 to 18 are also comprised. Subsequences that have 4 or 5 fewer amino acid than the sequences SEQ ID No. 1 to 18 are also comprised. In accordance with the invention also included are markers according to the invention that differ from sequences SEQ ID no. 1 to 18 in that they contain one or more insertions, wherein the insertions for example are 1 to 10 or more amino acids long, for example 1 to 10 or more amino acids, for example 1, 2, 3, 4 to 5 amino acids long, and the sequences are otherwise identical or homologous to sequences SEQ ID No. 1 to 18. Subsequences that have at least 95%, preferably at least 97%, particularly preferably at least 98% or 99%, of the length of the markers according to the invention with sequences SEQ ID No. 1 to 18 are particularly preferred.

In addition, the SSc markers can be present in the respective form in the form of a fusion protein, which for example contains at least one affinity epitope or “tag”, wherein the tag is selected for example from c-myc, His tag, Arg tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or Strep tag, HAT tag, NusA, S tag, SBP tag, thioredoxin, DsbA, or the fusion protein has one or more additional domains for example, such as a cellulose-binding domain, green fluorescent protein, maltose-binding protein, calmodulin-binding protein, glutathione S-transferase or lacZ.

In a further embodiment the invention relates to an assay, for example a multiplex assay, a bead-based assay, or protein array for identifying and characterising a substance, for example a hit, a lead substance, or an active substance for SSc. Here, a substance to be analysed is used. This can be any native or non-native biomolecule, a (synthetic) chemical molecule, a natural substance, a mixture or a substance library. Once the substance to be analysed has contacted an SSc marker, the binding success is evaluated, for example using commercially available image analysis software (GenePix Pro (Axon Laboratories), Aida (Raytest), or ScanArray (Packard Bioscience).

Binding according to the invention, binding success, interactions, for example protein-protein interactions (for example protein to SSc marker, such as antigen/antibody) or corresponding “means for detecting the binding success” can be visualised, for example, by means of fluorescence labelling, biotinylation, radio-isotope labelling or colloidal gold or latex particle labelling in the conventional manner. Bound antibodies are preferably detected with the aid of secondary antibodies, which are labelled with commercially available reporter molecules (for example Cy, Alexa, Dyomics, FITC or similar fluorescent dyes, colloidal gold or latex particles), or with reporter enzymes, such as alkaline phosphatase, horseradish peroxidase, etc. and the corresponding colorimetric, fluorescent or chemoluminescent substrates. A readout is performed visually, for example.

The following examples explain the invention, but do not limit the invention to the examples. In the following figures, systemic sclerosis is denoted by PPS (progressive systemic sclerosis).

FIG. 1 shows the intensity plots of the CENPA peptides that were achieved with the patient samples PG520-P01-2012-076, PG520-P01-2012-090, PG520-P01-2012-100 and PG520-PG1-2012-138 at a dilution of 1:5000.

FIG. 2 shows the intensity plots of the CENPA peptides that were achieved with the patient sample PG520-P01-2012-076.

FIG. 3 shows the intensity plots of the CENPA peptides that were achieved with the patient sample PG520-P01-2012-090.

FIG. 4 shows the intensity plots of the CENPA peptides that were achieved with the patient sample PG520-P01-2012-100.

FIG. 5 shows the intensity plots of the CENPA peptides that were achieved with the patient sample PG520-P01-2012-138.

FIG. 6 shows the intensity plots of the KDM6B peptides that were achieved with the patient samples PG520-P01-2012-076, PG520-P01-2012-090, PG520-PG1-2012-100 and PG520-P01-2012-138 at a dilution of 1:5000.

FIG. 7 shows the intensity plots of the KDM6B peptides that were achieved with the patient sample PG520-P01-2012-138.

EXAMPLES Example 1 Description and Objective of the Study

The objective of the study was to determine the relevant epitope/the relevant, epitopes of the novel autoantigen KDM6B. Within the scope of this study, peptide microarrays from PEPperPRINT (http://www.PEPperPRTNT.com) were used.

The CENPA antigen was analysed as the target antigen and used for the evaluation of the technology. In addition, the novel KDM6B antigen was used as an antigen for the diagnosis of SSc. While this antigen originally has a very large scope, it was only expressed as a short N-terminal fragment.

For epitope mapping, 15-mer peptides were generated, with an overlap of 14 amino acids from peptide to peptide.

All peptides that cover the sequence of both antigens were printed on a flat microarray by way of PEPperPRINT. In total, four microarrays were generated. For analysis, three sera from SSc patients which exhibited reactivity to both antigens were selected and incubated on the arrays. One serum from an SSc patient which exhibited no reactivity to these two antigens was used as the negative control.

The primary objective of the present study was to identify the relevant immunogenic regions/epitopes of CENPA, labelled by SSc sera, by way of peptide microarrays, and to compare the results to the previously published state of the art.

The secondary objective of the present study was to identify putative immunogenic epitopes of a novel antigen (KDM6B).

The third objective was to analyse whether the three disease sera behave identically or whether they exhibit biological diversity based on polyclonal immune response.

Example 2 Selection of the SSc Patient and Control Samples

In total, four different samples from SSc patients were selected on the basis of the reactivity thereof to the respective antigens CENPA and KDM6B (Table 1).

Three of the SSc patient samples (PG520-P01-2012-076, PG520-P01-2012-090, PG520-P01-2012-100), which tested positive for anti-CENPA and anti-KDM6B protein fragments, were selected as positive samples.

An SSc control sample (PG520-P01-2012-138), which showed negative test results for anti-CENPA and anti-KDM6B, was included. However, this does not preclude the possibility that this sample may react negatively to an epitope located at a distance from the region that was tested in the previous screen.

TABLE 1 Overview of positive and negative control series/plasma samples that were incubated on peptide arrays. Age Sample Tube Sample of external Barcode Identifier Group Gender Indication Diagnose

donor identifier

PSS F Progressive diffuse

x — x 52 21

PSS F Progressive

x — x 53 7

PSS F Progressive

x — x 57 31

PSS F Progressive

— — x 55 69 Tube Donor Date of Barcode identifier Birth

_

_

_

_

_

_

GeneID

Gene KDM68 KDM68

KDM68

Symbol Gene lysine lysine

lysine lysine

Name

protein A

protein A HV Mean

HVSD

HV HV HV Cutoff

mean + 2 50 Cutoff

mean + 3 50 Cutoff

mean + 3 50

NA

NA

NA

NA

indicates data missing or illegible when filed

Example 3 Epitope Mapping by Way of Peptide Microarrays

3.1 Description of Peptide Microarrays

The antigens CENPA and KDM6B were converted into 15-mer peptides with an overlap between peptides of 14 amino acids, which resulted in 1,831 different peptides, printed in duplicates (a total of 3,662 peptide spots). The corresponding peptide microarrays were additionally formed by FLAG and HA control peptides (124 spots each).

3.2 Experimental Conditions and Procedure

The experimental conditions were listed as indicated by PEPperPRINT:

Incubation buffer: PBS, pH 7.4 with 0.05% Tween 20 and 10% Rockland's blocking buffer

Washing buffer: PBS, pH 7.4 with 0.05% Tween 20 (2x1 min after each assay)

Blocking buffer: Rockland's blocking buffer MB-070 (60 min prior to first assay)

Conditions for the assay: serum dilutions of 1:5000 and 1:1000 in the incubation buffer; incubation for 16 hrs at 4° C. and shaking at 500 rpm.

Secondary antibody: F(ab')2 goat anti-human IgG(H+L) conj. DyLight680; 30 min staining at RT and a dilution of 1:5000

Control antibody: monoclonal anti-HA (12CA5)-DyLight680, monoclonal anti-FLAG (M2) - DyLight800; staining in the incubation buffer for 1 h at RT and a dilution of 1:1000

Scanner: LI-COR Odyssey Imaging System; scanning offset 1 mm, resolution 21 pm, scanning intensity green/red 7/7

Microarray data: MicroarryData_PG520-P01-2012-076.xlsx, MicroarrayData_PG520-P01-2012-090.xlsx, MicroarrayData_PG520-PO1-2012-100.xlsx, MicroarrayData_PG520-P01-2012-138.xlsx, MicroarrayData_Summary.xlsx

Microarray Identification: 000616_02, 000616_03, 000646_05, 000646_06 (two array copies per microarray)

The pre-staining of one of the peptide arrays was carried out with the F(ab′)2 goat anti-human IgG(H+L) conj. DyLight680 antibody at a dilation of 1:5000 to analyse the background interactions with the peptides that included no antigens, which could impair the primary assays. The subsequent incubation of the peptide microarrays with the human sera PG520-P01-2012-076, PG520-P01-2G12-090, PG520-P01-2012-100 and PG520-P01-2012-138 at dilutions of 1:5000 and 1:1000 in the incubation buffer was followed by staining with the secondary antibody and the readout at a scanning intensity of 7 (red). HA and FLAG control peptides, which frame the peptide arrays, were finally stained for internal quality control to verify the quality of the assay and the integrity of the peptide microarray (scanning intensities red/green 7/7).

Example 4 Data Analysis

The data analysis was carried out by way of PEPperPRINT as described hereafter. The quantification of the spot intensities and the peptide detection were carried out with the aid of the PepSlide® analyser. A software algorithm breaks down the fluorescence intensities of every spot into raw, foreground and background signals and calculates the standard deviation from mean foreground intensities. Intensity maps were generated based on averaged mean foreground intensities, and the binders were labeled in the peptide maps by a red intensity color code for high spot intensities and in white for low spot intensities, PEPperPRINT additionally recorded averaged spot intensities of all assays against the linked antigen sequences from the N-terminus of CENPA to the C-terminus of KDM6B so as to visually represent all the spot intensities and the relationship between signal and sound.

The intensity plots were correlated with peptide and intensity maps and with a visual inspection of the microarray scans so as to identify peptides and consensus patterns that interacted with the plasma samples.

Where it was unclear whether a certain amino acid contributed to the binding of antibodies, the corresponding letters were written in gray color.

Example 5 Peptide Mapping of CENPA

As shown in FIG. 1, the intensity plots (dilution 1:5000) of the CENPA peptides underscored the very strong and almost identical reaction of the sera PG520-P01-2012-076, PG520-P01-2012-090 and PG520-P01-2012-100 with the two primary epitopes RSPSPTPTPGPSR (SEQ ID No. 13) and GPSRRGPSLGAS (SEQ ID No. 11) and a third, but superimposed (overlapping) epitope TPTPGPSRRGPS (SEQ ID No. 12).

All these three individual peptides are represented by the amino acids (aa) 16-36 (FIG. 1). The serum PG520-P01-2012-076 showed a minor difference in the intensity ratio of the two primary epitopes and caused an additional N-terminus epitope RSPSPTPTPGPSR (SEQ ID No. 15) or PRRRSRKPEAPR (SEQ ID No. 14) (represented by aa 3-14). This epitope also has a weak reaction in the sample PG520-P01-2012-090 at a dilution of 1:1000 (FIG. 3). Moreover, the sample PG520-P01-2012-100 exhibits an additional reaction to this N-terminus region at a dilution of 1:1000 (FIG. 4).

The patient sample PG520-P01-2012-138, which tested negative for anti-CENPA in the Luminex Perl assay, exhibits a weak reaction (FIG. 5). Only three individual peptide interactions based on the peptides APRRRSPSPTPTPGP (SEQ ID No. 16), RRRSPSPTPTPGPSR (SEQ ID No. 17) and SPSPTPTPGPSRRGP (SEQ ID No. 18) were observed at a dilution of 1:1000, not, however, at a dilution of 1:5000.

Example 6 Distribution of the Epitopes of CENPA

The distribution of the epitopes that were identified by way of peptide mapping is shown in Table 2.

TABLE 2  The amino acid sequence of CENPA (Gen ID: 1058) MG PRRRSRICPEAPR R

SHQHSRRRQGWLKE IRKLQKSTHLLIRKLPFSRLAREICVKFTRGVDFNWQAQALLALQEAAEA FLVHLFEDAYLLTLHAGRVTLFPKDVQLARRIRGLEEGLG

The larger epitope identified by peptide mapping is double-underlined (aa 16-36), while the second, weaker epitope is single-underlined (aa 3-14).

Muro et al. expressed as series of cut peptides in E. coli and conducted an immunoblot analysis with 91 ACA-positive sera (Muro et. al., 2000). Eighty of the sera (88%) with ACA reacted to the N-terminus region with 52 amino acids, while none of the sera reacted to the C-terminus. Two synthetic peptides (amino acid sequences aa 3±17 (peptide A) and aa 25±38 (peptide B)) reacted in ELISA to 78 (86%) and 79 (87%) of the ACA-positive sera. Peptide A corresponds to the second epitope (aa 3-14), which was less reactive in our presently tested, patient samples than described by Muro et al. (2000).

Peptide B is part of the larger epitope (aa 16-36) identified by peptide arrays.

By way of the systematic approach of peptide mapping, it is possible to identify not only individual epitopes in the order of magnitude of the presently used peptides (14 aa), but also larger regions that are covered by multiple, overlapping peptides.

TABLE 3  DNA sequence of Homo sapiens centromere protein A (CENPA), transcription variant 1, mRNA (ref|NM_001809.3|) gray: coding sequence (base pair 184-606); blue: sequence of the expression clone 00700_007_E24, BBA25_203; red: the larger epitope identified by peptide mapping; black: sequence portions not represented by the expression clone.    1 ccgtgaagtg ggcggagcga gcgatttgaa cgcgagcggc gcggacttct gccaagcacc   61 ggctcatgtg aggctcgcgg cacagcgttc tctgggctcc ccagaagcca gcctttcgct  121 cccggacccg gcagcccgag caggagccgt gggaccgggc gccagcaccc tctgcggcgt  181 gtcatgggcc cgcgccgccg gagccgaaag cccgaggccc cgaggaggcg cagcccgagc  241 ccgaccccga cccccggccc ctcccggcgg ggcccctcct taggcgcttc ctcccatcaa  301 cacagtcggc ggagacaagg ttggctaaag gagatccgaa agcttcagaa gagcacacac  361 ctcttgataa ggaagctgcc cttcagccgc ctggcaagag aaatatgtgt taaattcact  421 cgtggtgtgg acttcaattg gcaagcccag gccctattgg ccctacaaga ggcagcagaa  481 gcatttctag ttcatctctt tgaggacgcc tatctcctca ccttacatgc aggccgagtt  541 actctcttcc caaaggatgt gcaactggcc cggaggatcc ggggccttga ggagggactc  601 ggctgagctc ctgcacccag tgtttctgtc agtctttcct gctcagccag gggggatgat  661 accggggact ctccagagcc atgactagat ccaatggatt ctgcgatgct gtctggactt  721 tgctgtctct gaacagtatg tgtgtgttgc tttaaatatt tttctttttt ttgagaagga  781 gaagactgca tgactttcct ctgtaacaga ggtaatatat gagacaatca acaccgttcc  841 aaaggcctga aaataatttt cagataaaga gactccaagg ttgactttag tttgtgagtt  901 actcatgtga ctatttgagg attttgaaaa catcagattt gctgtggtat gggagaaaag  961 gctatgtact tattatttta gctctttctg taatatttac attttttacc atatgtacat 1021 ttgtactttt attttacaca taagggaaaa aataagacca ctttgagcag ttgcctggaa 1081 ggctgggcat ttccatcata tagacctctg cccttcagag tagcctcacc attagtggca 1141 gcatcatgta actgagtgga ctgtgcttgt caacggatgt gtagcttttc agaaacttaa 1201 ttggggatga atagaaaacc tgtaagcttt gatgttctgg ttacttctag taaattcctg 1261 tcaaaatcaa ttcagaaatt ctaacttgga gaatttaaca ttttactctt gtaaatcata 1321 gaagatgtat cataacagtt cagaatttta aagtacattt tcgatgcttt tatgggtatt 1381 tttgtagttt ctttgtagag agataataaa aatcaaaata tttaatgaaa a

Example 6 Peptide Mapping of KDM6B

As shown in FIG. 6, the intensity plots (dilution 1:5000) underscored the moderate to strong and partially similar reaction of the sera PG520-P01-2012-076, PG520-P01-2012-090 and PG520-P01-2012-100 with the primary epitopes LPAPLPPSHGSS (SEQ ID No. 2) and SPQPSASSSSQF (SEQ ID No. 3). The LPAPLPPSHGSS epitope (SEQ ID No. 2) (aa 55-67) was common to all positive serum samples.

In contrast, the SPQPSASSSSQF (SEQ ID No. 3) aa 861-873) epitope was only observed in the sera PG520-P01-2012-076 and PG520-P01-2012-090. The neighboring epitope SSQFSTSGGPWAR (SEQ ID No. 4) (aa 870-881), however, was likewise detected in sample PG520-P01-2012-076 and GGPWARERRAGEEPV (SEQ ID no. 6) (aa 877-890) and was detected slightly by PG520-P01-2012-100 (1:1000 dilution). The result is an immunogenic region from aa 861 to 890.

Other epitopes, such as REKLNPPTPSIYL (SEQ ID No. 5), were identified only in one of the samples.

The patient sample PG520-P01-2012-138, which tested negative for KDM6B in the Luminex Perl assay, exhibited a weak to moderate reaction to several individual peptides at a dilution of 1:1000, and to two different peptides at a dilution of 1:5000. The majority of interactions were either based on highly alkaline peptides such as KRNYGAKRGGPPVKR (SEQ ID No. 19) or hydrophobic peptides comprising a proline at the C-terminus (such as FPKTPEVGPGPPPGP (SEQ ID No. 20) or GHPSKPYYAPGAPTP (SEQ ID No. 21). Given the indistinct morphology of the spots, the weak spot intensities and the general inconsistency of the data, all interactions were rated to be non-specific (FIG. 7).

The distribution of the epitopes that were identified by way of peptide mapping is shown in Table 4. In the Sero-Tag Discovery Screens, three clones express KDM6B antigen (or fragments of KDM6B). All three expression clones express a similar coding region (aa 42-435) and comprise the largest LPAPLPPSHGSS (SEQ ID No. 2) epitope.

The epitope mapping of KDM6B results in two larger epitopes and only one epitope that was detected in one of three KDM6B-positive samples. All three available expression clones of KDM6B express the similar code region (aa 42-435) and comprise the one of the larger epitopes (LPAPLPPSHGSS, SEQ ID No. 2). The second immunogenic region, which is covered by >3 peptides (aa 861-890), is not represented by these expression clones.

TABLE 4  The amino acid sequence of CENPA (Gen ID: 23135) The larger epitope identified by way of peptide mapping is shown in bold and underlined (aa 55-67), while the second region is composed of > peptides and double-underlined (aa 861-890). A third epitope, which was detected in only one sample, is single-underlined. Bold: expressed sequence using expression clones in the Sero tag. MHRAVDPPGARAAREAFALGGLSCAGAWSSCPPHPPPRSAWLPGGRCSASIGQPP LPAPLPP SHGSS SGHPSKPYYAPGAPTPRPLHGKLESLHGCVQALLREPAQPGLWEQLGQLYESEHDSE EATRCYHSALRYGGSFAELGPRIGRLQQAQLWNFHTGSCQHRAKVLPPLEQVWNLLHLEHKR NYGAKRGGPPVKRAAEPPVVQPVPPAALSGPSGEEGLSPGGKRRRGCNSEQTGLPPGLPLPP PPLPPPPPPPPPPPPPLPGLATSPPFQLTKPGLWSTLHGDAWGPERKGSAPPERQEQRHSLP HPYPYPAPAYTAHPPGHRLVPAAPPGPGPRPPGAESHGCLPATRPPGSDLRESRVQRSRMDS SVSPAATTACVPYAPSRPPGLPGTTTSSSSSSSSNTGLRGVEPNPGIPGADHYQTPALEVS HHGRLGPSAHSSRKPFLGAPAATPHLSLPPGPSSPPPPPCPRLLRPPPPPAWLKGPACRAAR EDGEILEELFFGTEGPPRPAPPPLPHREGFLGPPASRFSVGTQDSHTPPTPPTPTTSSSNSN SGSHSSSPAGPVSFPPPPYLARSIDPLPRPPSPAQNPQDPPLVPLTLALPPAPPSSCHQNTS GSFRRPESPRPRVSFPKTPEVGPGPPPGPLSKAPQPVPPGVGELPARGPRLFDFPPTPLEDQ FEEPAEFKILPDGLANIMKMLDESIRKEEEQQQHEAGVAPQPPLKEPFASLQSPFPTDTAPT TTAPAVAVTTTTTTTTTTTATQEEEKKPPPALPPPPPLAKFPPPSQPQPPPPPPPSPASLLK SLASVLEGQKYCYRGTGAAVSTRPGPLPTTQYSPGPPSGATALPPTSAAPSAQGSPQPSASS SSQPSTSGGPWARERRAGEEPVPGPMTPTQPPPPLSLPPARSESEVLEEISRACETLVERVG RSATDPADPVDTAEPADSGTERLLPPAQAKEEAGGVAAVSGSCKRRQKEHQKEHRRHRRACK DSVGRRPREGRAKAKAKVPKEKSRRVLGNLDLQSEEIQGREKSRPDLGGASKAKPPTAPAPP SAPAPSAQPTPPSASVPGKKAREEAPGPPGVSRADMLKLRSLSEGPPKELKIRLIKVESGDK ETFIASEVEERRLRMADLTISHCAADVVRASRNAKVKGKFRESYLSPAQSVKPKINTEEKLP REKLNPPTPSIYLESKRDAFSPVLLQFCTDPRNPITVIRGLAGSLRLNLGLFSTKTLVEASG EHTVEVRTQVQQPSDENWDLTGTRQIWPCESSRSHTTIAKYAQYQASSFQESLQEEKESEDE ESEEPDSTTGTPPSSAPDPKNHHIIKFGTNIDLSDAKRWKPQLQELLKLPAFMRVTSTGNML SHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFAVHEHYWETISAFC DRHGVDYLTGSWWPILDDLYASNIPVYRFVQRPGDLVWINAGTVHWVQATGWCNNIAWNVGP LTAYQYQLALERYEWNEVKNVKSIVPMIHVSWNVARTVKISDPDLFKMIKFCLLQSMKHCQV QRESLVRAGKKIAYQGRVKDEPAYYCNECDVEVFNILFVTSENGSRNTYLVHCEGCARRRSA GLQGVVVLEQYRTEELAQAYDAFTLVRARRARGQRRRALGQAAGTGFGSPAAPFPEPPPAFS PQAPASTSR

LITERATURE

Mehra S, Walker J, Patterson K, Fritzler M J (2013). Autoantibodies in systemic sclerosis. Autoimmun Rev. 12(3):340-54.

Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M,

Reichenberger F, Buslau M, Worm M, Blank N, Hein R, Muller-Ladner U, Kuhn A, Sunderkötter C, Juche A, Pfeiffer C, Fiehn C, Sticherling M, Lehmann P, Stadler R, Schulze-Lohoff E, Seitz

C, Foeldvari I, Krieg T, Genth E, Hunzelmann N (2011). Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma; correlation with characteristic clinical features. Arthritis Res Ther, 13(5):R172

LeRoy E C, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger T A Jr, Rowell N, Wollheim F (1988), Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 15(25:202-5.

Watts R., (2006). Autoantibodies in the autoimmune rheumatic diseases, Medicine, 34 (11); 441-444 

1-15. (canceled)
 16. A fusion protein for detecting systemic sclerosis (SSc), comprising a peptide sequence selected independently of one another from any one of SEQ ID NOs: 1-10, 13, 15-18 and at least one protein tag bound to the peptide sequence.
 17. The fusion protein of claim 16, wherein the peptide sequence has a length of no more than 25 amino acids.
 18. The fusion protein of claim 16, wherein the peptide sequence has a length of no more than 15 amino acids.
 19. The fusion protein of claim 16, wherein the tag is selected from c-myc, His tag, Arg tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or Strep tag, HAT tag, NusA, S tag, SBP tag, thioredoxin, and DsbA.
 20. The fusion protein of claim 16, wherein the fusion protein has one or more additional domains selected from a cellulose-binding domain, green fluorescent protein, maltose-binding protein, calmodulin-binding protein, glutathione S-transferase and lacZ.
 21. The fusion protein of claim 16, wherein the peptide sequence is a binding region.
 22. The fusion protein of claim 16, wherein the peptide sequence is an epitope.
 23. The fusion protein of claim 16, wherein the fusion protein binds to autoantibodies that are present during the course of development, establishment, or therapy of SSc.
 24. The fusion protein of claim 23, wherein the fusion protein binds to autoantibodies that are up-regulated or down-regulated during the course of development, establishment, or therapy of SSc.
 25. A pharmaceutical composition for the treatment of systemic sclerosis (SSc), comprising a peptide sequence selected independently of one another from any one of SEQ ID NOs: 1-10, 13, 15-18, at least one protein tag bound to the peptide sequence, and at least one additive or auxiliary agent in the pharmaceutical composition.
 26. A method for screening active substances for use with SSc, comprising: a) contacting a substance to be tested with at least one fusion protein of claim 16; and b) detecting an interaction of the substance to be tested with the one or more fusion proteins. 